Clinical efficacy of 125I seed implantation combined with gefitinib in patients with non-small cell lung cancer and its impact on immune system
Author(s): ZHAO Yun, YU Faming, JIANG Dongliang, YANG Guoqing, GUO Tianli
Pages: 419-421,459
Year: 2017 Issue: 4
Journal: Oncology Progress
Keyword: lung cancer; 125I seed implantation; gefitinib; T-lymphocyte subpopulations; NK cells; CIK cells; immu-nomodultory factors;
Abstract: Objective To evaluate the clinical efficacy of 125I seed implantation combined with gefitinib in patients with non-small cell lung cancer and its impact on immune system. Methods 53 cases of patients with non-small cell lung cancer were selected, and all patients were treated with the therapy of 125I seed implantation combined with gefitinib. After treatment, the clinical efficacy and adverse reactions of all patients were evaluated. The levels of peripheral blood T-lymphocyte subpopulations, NK cells, CIK cells and related immunoregulatory factors before treatment and 1, 3 and 6 months after treatment were measured, and the changes were evaluated. Results The clinical efficacy of 1, 3 and 6 months after treatment is 54.72%, 64.15%and 75.47%respectively. After treatment, iodine seeds got out of the target ar-ea and migrated in one patient, pneumothorax occurred in one patient and hemoptysis occurred in two patients. None of the patients showed radiation injury of the lung, leukopenia or other serious complications. Comparing with data before treatment, the levels of peripheral blood CD4+, CD4+/CD8+and NK cells were higher (P<0.05) and the level of CD8+ was lower (P<0.05) at 6 months after treatment. The levels of peripheral blood TNF-α, IL-2, IL-4, IL-6 and IL-10 at 6 months after treatment were significantly lower than those before treatment (P<0.05). Conclusion In patients with non-small cell lung cancer, the therapy of 125I seed implantation combined with gefitinib showed good clinical efficacy and low rates of adverse reactions. It could also regulate T-lymphocyte subpopulations, NK cells and immunoregulatory factors, and im-prove immune function.
Pages: 419-421,459
Year: 2017 Issue: 4
Journal: Oncology Progress
Keyword: lung cancer; 125I seed implantation; gefitinib; T-lymphocyte subpopulations; NK cells; CIK cells; immu-nomodultory factors;
Abstract: Objective To evaluate the clinical efficacy of 125I seed implantation combined with gefitinib in patients with non-small cell lung cancer and its impact on immune system. Methods 53 cases of patients with non-small cell lung cancer were selected, and all patients were treated with the therapy of 125I seed implantation combined with gefitinib. After treatment, the clinical efficacy and adverse reactions of all patients were evaluated. The levels of peripheral blood T-lymphocyte subpopulations, NK cells, CIK cells and related immunoregulatory factors before treatment and 1, 3 and 6 months after treatment were measured, and the changes were evaluated. Results The clinical efficacy of 1, 3 and 6 months after treatment is 54.72%, 64.15%and 75.47%respectively. After treatment, iodine seeds got out of the target ar-ea and migrated in one patient, pneumothorax occurred in one patient and hemoptysis occurred in two patients. None of the patients showed radiation injury of the lung, leukopenia or other serious complications. Comparing with data before treatment, the levels of peripheral blood CD4+, CD4+/CD8+and NK cells were higher (P<0.05) and the level of CD8+ was lower (P<0.05) at 6 months after treatment. The levels of peripheral blood TNF-α, IL-2, IL-4, IL-6 and IL-10 at 6 months after treatment were significantly lower than those before treatment (P<0.05). Conclusion In patients with non-small cell lung cancer, the therapy of 125I seed implantation combined with gefitinib showed good clinical efficacy and low rates of adverse reactions. It could also regulate T-lymphocyte subpopulations, NK cells and immunoregulatory factors, and im-prove immune function.
Related Articles